Patient-derived Organoid Drug Sensitivity Guided Treatment for Recurrent Small Cell Lung Cancer

NARecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 16, 2024

Primary Completion Date

December 16, 2025

Study Completion Date

June 16, 2026

Conditions
Small Cell Lung Cancer
Interventions
OTHER

Chemotherapy and targeted-therapy guided by organoid drug sensitivity test

This study conducts drug sensitivity tests on various clinically approved drugs. The most sensitive drug for the patient is selected for treatment. This study aims to evaluate the clinical effectiveness of treatment plans guided by organoid drug sensitivity tests.

Trial Locations (1)

450003

RECRUITING

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors
collaborator

Kingbio Medical (Beijing) Co., Ltd.

UNKNOWN

lead

Henan Cancer Hospital

OTHER_GOV